MEIP earnings

-- Conference Call Today at 5:00 p.m. Eastern Time -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023. "Over just the next few quarters we look forward to data readouts from two ongoing clinical studies of voruciclib and ME-344, advancing our strategy of assessing drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs," said David M. Urso, president and chief executive officer of MEI Pharma. "Focusing on the execution of these two clinical studies – voruciclib evaluated in co

MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the close of the U.S. financial markets on September 26, 2023. Company management will host a conference call and webcast that day at 5:00 p.m. ET to discuss the results and provide a corporate overview. Conference Call & Webcast Information When: September 26, 2023, 5:00 p.m. ET Dial-in: 1-833-974-2378 (United States) or 1-412-317-5771 (International) Please ask to join into the MEI Pharma earnings call Please join the conference call at least 10 minutes early to re

Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022. The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET. Conference Call & Webcast Information When: September 8, 2022, 5:00 p.m. ET Dial-in: 1-833-974-2378 (United States) or 1-412-317-5771 (International) Please ask to join into the MEI Pharma earnings call Please join the conference call at least 10 minutes ear

– MEI to Host Zandelisib Program Update Webcast Today at 4:30 p.m. Eastern Time – MEI Pharma, Inc. (NASDAQ:MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase ("PI3K") inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study. In the meeting, the FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor dr

– Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – MEI to Host Webcast Today at 8:00am Eastern Time – MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies de

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2021. "Fiscal year 2021 was very successful for MEI; it was highlighted by multiple data updates that continue to support the potential of the unique intermittent dosing therapy schedule we designed for zandelisib, both as a monotherapy and in combination with other therapies across a range of B-cell malignances. To that end, we are continuing to expand the clinical program with studies designed to broaden zandelisib's potential, like the Phase 3 COASTAL study in second line or lat

SAN DIEGO, Aug. 26, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2021 fiscal year end financial results after the close of the U.S. financial markets on September 2, 2021. The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET.  Conference Call & Webcast Information When: September 2, 2021, 5:00 p.m. ET Dial-in: 1-833-974-2378 (United States) or 1-412-317-5771 (International) When requested, please ask the operator to join the MEI Pharma earnings cal